Elsevier

Experimental Cell Research

Volume 192, Issue 2, February 1991, Pages 481-491
Experimental Cell Research

Regular article
MC29-immortalized clonal avian heart cell lines can partially differentiate in vitro

https://doi.org/10.1016/0014-4827(91)90067-5Get rights and content

Abstract

We established quail clonal heart muscle cell lines from cardiac rhabdomyosarcomas developed in embryos injected in ovo with the MC29 virus containing the v-myc oncogene. These clones were characterized by means of antibodies detecting markers of striated muscle cells. Two clones were selected for further characterization on the basis of a distribution of myogenic markers similar to that in normal early embryonic cardiac muscle cells. However, these muscle markers progressively disappeared with time in culture. Cardiomyocytic differentiation could be reinduced in culture, by associating the avian cardiac cells with 3T3 cells in a defined synthetic medium. Muscle markers were then reexpressed in all cardiac cells as soon as Day 1 after coculture. Multiplication of cardiac cells continued at the same time. This is characteristic of cardiac clones since MC29-infected quail myoblasts and MC29-infected quail fibroblasts exhibited a split response to 3T3 association, i.e., decreased growth and enhanced differentiation. The cardiac clones were maintained in vitro for more than 60 generations (6 months) without morphological changes. To our knowledge, this is the first description of clonal embryonic avian heart cell lines.

References (64)

  • H. Schneider et al.

    Exp. Cell Res

    (1965)
  • H.F. Clark et al.

    Exp. Cell Res

    (1967)
  • B.W. Kimes et al.

    Exp. Cell Res

    (1976)
  • A-E. Al-Moustafa et al.

    Cell Differ

    (1988)
  • T.G. Easton et al.

    J. Biol. Chem

    (1972)
  • S. Alema et al.

    Adv. Cancer Res

    (1987)
  • S. LaRocca et al.

    Cell

    (1989)
  • R.A. Weiss

    Exp. Cell Res

    (1970)
  • P.P. Mehta et al.

    Cell

    (1986)
  • J.G. Rheinwald et al.

    Cell

    (1975)
  • R.L. De Haan

    Dev. Biol

    (1967)
  • F. Tato et al.

    Differentiation

    (1983)
  • P. Brazeau et al.

    Regul. Peptides

    (1981)
  • C. Ziller et al.

    Cell

    (1983)
  • R.A. Laskey
  • P.-M. Rong et al.

    Dev. Biol

    (1987)
  • T. Graf et al.

    Biochim. Biophys. Acta

    (1978)
  • N. Denis et al.

    Exp. Cell Res

    (1987)
  • L. Gazzolo et al.

    Cell

    (1979)
  • W. Kuri-Harcuch et al.

    Differentiation

    (1989)
  • B. Nadal-Ginard

    Cell

    (1978)
  • I.S. Polinger

    Exp. Cell Res

    (1973)
  • A.M. Kelly et al.

    Dev. Biol

    (1976)
  • W.A. Clark et al.

    Dev. Biol

    (1983)
  • B.T. Atherton et al.

    J. Cell Sci

    (1986)
  • H.C. Hartzell et al.

    Nature (London)

    (1986)
  • R.E. White et al.

    Science

    (1988)
  • H. Reuter

    Nature (London)

    (1983)
  • D.S. Kohtz et al.

    J. Cell Biol

    (1989)
  • M.T. Burrows

    Science

    (1912)
  • A. Carrel

    J. Exp. Med

    (1914)
  • S. Saule et al.
  • Cited by (30)

    • Ultrastructural comparison of developing mouse embryonic stem cell- and in vivo-derived cardiomyocytes

      2006, Cell Biology International
      Citation Excerpt :

      However, cell isolation techniques used to obtain these primary cultures are not suitable for the study of prenatal early cardiac developmental stages due to the small quantity of myocardial material and to the difficulty in maintaining an immature cell stage during the culture procedure. Therefore, several attempts were made to generate permanent cell lines derived from embryonic rat heart (Kimes and Brandt, 1976), embryonic avian heart (Jaffredo et al., 1991), adult rat myocardium (Caviedes et al., 1993), myocardial tumor tissue of transgenic mouse (Field, 1993), and proliferating cardiac cells by virus transfection technology (Sen et al., 1988). The disadvantages of these models regarding functional, structural and molecular aspects hampered their application in clinical settings.

    • Novel cell lines derived from adult human ventricular cardiomyocytes

      2005, Journal of Molecular and Cellular Cardiology
      Citation Excerpt :

      Terminally differentiated primary cultures which may be maintained for several weeks, undergo morphological and functional changes over time [4,5], and yield a heterogeneous population of cells. Attempts to establish immortalized cardiomyocyte cell lines that can proliferate in culture include AT-1 cells, established from a mouse atrial tumor [6], MC29, a quail cell line from a rhabdomyosarcoma tumor [7], cell lines established from transgenic mice that express the SV40 T-ag [8–10], and by transformation of fetal cardiomyocytes with the SV40 oncogene [11–13]. These transformed cells suffer from numerous deficits including the lack of typical cardiomyocyte phenotype, limited capacity to be passaged, which compromises their applications to developmental and cellular studies, or de-differentiating on prolonged culture.

    • DSCAM: An endogenous promoter drives expression in the developing CNS and neural crest

      2002, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      To identify functional elements of the endogenous DSCAM promoter for use in directing transgene expression in the mouse, we subcloned a fragment containing 1.8 kb of human genomic DNA immediately upstream of the DSCAM translational start site into the reporter vector pβgal-enhancer (Clontech) (see Fig. 1). The resulting transgenic construct, Pr1.8-βgal, was first tested for promoter activity in cell lines derived from several different tissue types, including COS-7 (ATCC), NIH/3T3 (ATCC), and a quail embryonic cardiac mesenchyme (MEQC) cell line [10] (see Methods). Transfection conditions were initially optimized for each cell line using the pβgal-control vector (Clontech) and a variety of transfection reagents, including Effectene (Qiagen), Superfect (Qiagen), and Lipofectamine (Gibco-BRL) (see Methods).

    View all citing articles on Scopus

    Financial support was provided by the Centre National de la Recherche Scientifique and the Association Française contre la Myopathie.

    3

    T.J is a recipient of a fellowship from the Fondation pour la Recherche Médicale.

    2

    Present address: Ecole Normale Supérieure, Département de Biologie, 46, rue d'Ulm 75005 Paris, France.

    4

    N.B is a recipient of a fellowship from the Fondation Singer-Polignac.

    View full text